Rheumatoid arthritis drug may reduce inflammation after stroke
Research into the use of an anti-arthritic drug to reduce brain injury following an ischemic stroke has shown promise; however, further research is needed.
Source: Zephyr / Science Photo Library
The pro-inflammatory cytokine interleukin (IL)-1 plays a significant role in brain injury following ischemic stroke by inducing peripheral inflammatory mediators, such as IL-6. However, pre-clinical studies show its effects are reduced by the IL-1 receptor antagonist (IL-1Ra).
Researchers investigated the effects of a drug form of IL-1Ra (anakinra), used to treat rheumatoid arthritis, on acute ischemic stroke through a double-blind, randomised controlled trial.
The drug was administered subcutaneously, 100mg twice daily for 3 days, in 80 patients presenting within 5 hours of ischemic stroke onset. Levels of IL-6 and other plasma inflammatory markers were analysed at five time points, before, during and after treatment.
It was found that, over the three days, IL-1Ra significantly reduced levels of IL-6 and other inflammatory mediators.
IL-1Ra was found to be safe and well-tolerated, the researchers concluded in Stroke (22 March 2018). However, further experimental studies are required to investigate possible interactions with thrombolytic agents.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204800
Recommended from Pharmaceutical Press
Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.£22.00
The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.£25.00
The Handbook of Pharmaceutical Excipients contains essential data on the physical properties of excipients, their safe use and potential toxicity.£415.00
Essential guidance for distributors of medicines for human use in Europe, compiled by the MHRA.£72.00
An essential guide on pharmacovigilance of medicinal products for human use. Practical advice for developing effective pharmacovigilance systems.£38.00